FGFR2 and cancer: Because the cancer multi-gene panel testing using percutaneous tissue sample revealed MSI-high and TMB-high, whereas no fibroblast growth factor receptor 2 (FGFR2)-related abnormality, he received pembrolizumab monotherapy as second-line therapy.